Lakefront Biotherapeutics NV
GLPGF
$28.08
$0.000.00%
OTC PK
| 03/31/2026 | 12/31/2025 | 06/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 292.58M | 302.30M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 292.58M | 302.30M |
| Cost of Revenue | -- | -- | -- | 534.33M | 517.91M |
| Gross Profit | -- | -- | -- | -241.74M | -215.60M |
| SG&A Expenses | -- | -- | -- | 152.61M | 153.46M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -41.57M | -39.91M |
| Total Operating Expenses | -- | -- | -- | 645.36M | 631.45M |
| Operating Income | -- | -- | -- | -352.78M | -329.15M |
| Income Before Tax | -- | -- | -- | -316.07M | -193.15M |
| Income Tax Expenses | -- | -- | -- | -2.55M | -3.19M |
| Earnings from Continuing Operations | -- | -- | -- | -313.52 | -189.96 |
| Earnings from Discontinued Operations | -- | -- | -- | 1.97M | 8.10M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | -311.54M | -181.86M |
| EBIT | -- | -- | -- | -352.78M | -329.15M |
| EBITDA | -- | -- | -- | -299.98M | -287.31M |
| EPS Basic | -- | -- | -- | -4.73 | -2.76 |
| Normalized Basic EPS | -- | -- | -- | -2.40 | -1.84 |
| EPS Diluted | -- | -- | -- | -4.73 | -2.77 |
| Normalized Diluted EPS | -- | -- | -- | -2.40 | -1.84 |
| Average Basic Shares Outstanding | -- | -- | -- | 263.63M | 263.62M |
| Average Diluted Shares Outstanding | -- | -- | -- | 263.68M | 263.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |